Get started
Author

Eleonora Marrucci

The cytologic category of oncocytic (Hurthle) cell neoplasm mostly includes low-risk lesions at histology: an institutional experience
2013 · Esther Diana Rossi, Maurizio Martini, et al. · European Journal of Endocrinology · 31
How to improve MRI accuracy in detecting deep infiltrating colorectal endometriosis: MRI findings vs. laparoscopy and histopathology
2013 · Anna Lia Valentini, Benedetta Gui, et al. · La radiologia medica · 18
Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study
2021 · F. Nelli, A. Fabbri, et al. · Annals of Oncology · 16
PDF
Ectopic salivary gland tissue in a Rathke's cleft cyst.
2013 · Valentina Ranucci, Antonella Coli, et al. · Europe PMC (PubMed Central) · 16
Emerging kinase inhibitors of the treatment of gastric cancer
2015 · Bruno Vincenzi, Marco Imperatori, et al. · Expert Opinion on Emerging Drugs · 12
Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives
2015 · Marco Imperatori, Loretta D’Onofrio, et al. · Hepatic Oncology · 11
PDF
Role of SOCS3 Evaluated by Immunohistochemical Analysis in a Cohort of Patients Affected by Prostate Cancer: Preliminary Results
2012 · Alessandro Calarco, Francesco Pinto, et al. · Urologia Journal · 11
Early Changes in LIPI Score Predict Immune-Related Adverse Events: A Propensity Score Matched Analysis in Advanced Non-Small Cell Lung Cancer Patients on Immune Checkpoint Blockade
2024 · Fabrizio Nelli, Agnese Fabbri, et al. · Cancers · 10
PDF
Effects of Acetaminophen Exposure on Outcomes of Patients Receiving Immune Checkpoint Inhibitors for Advanced Non-Small-Cell Lung Cancer: A Propensity Score-Matched Analysis
2023 · Fabrizio Nelli, Antonella Virtuoso, et al. · Current Oncology · 10
PDF
Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients
2022 · Enzo Maria Ruggeri, Fabrizio Nelli, et al. · Scientific Reports · 10
PDF
Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study
2021 · F. Nelli, A. Fabbri, et al. · Annals of Oncology · 9
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study
2021 · E.M. Ruggeri, F. Nelli, et al. · ESMO Open · 9
PDF
Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study
2022 · Fabrizio Nelli, Agnese Fabbri, et al. · International Immunopharmacology · 8
PDF
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study
2022 · F. Nelli, D. Giannarelli, et al. · Annals of Oncology · 8
Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study
2023 · Fabrizio Nelli, Carlo Signorelli, et al. · Cancers · 7
PDF
Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study
2022 · F. Nelli, A. Virtuoso, et al. · Cancer Chemotherapy and Pharmacology · 7
Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival
2022 · MARIO GIOVANNI CHILELLI, CARLO SIGNORELLI, et al. · Cancer Diagnosis & Prognosis · 7
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors
2023 · Fabrizio Nelli, Diana Giannarelli, et al. · Cancer Immunology Immunotherapy · 6
PDF
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study
2023 · Agnese Fabbri, Fabrizio Nelli, et al. · Frontiers in Oncology · 6
Evaluating triptorelin as a treatment option for breast cancer
2019 · Emanuela Ferraro, Dario Trapani, et al. · Expert Opinion on Pharmacotherapy · 6
Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study
2023 · Fabrizio Nelli, Agnese Fabbri, et al. · Current Oncology · 5
PDF
Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study
2024 · Fabrizio Nelli, Agnese Fabbri, et al. · Clinical and Experimental Medicine · 4
PDF
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature
2022 · Andrea Botticelli, Agnese Fabbri, et al. · Frontiers in Oncology · 4
PDF
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study
2023 · Fabrizio Nelli, Agnese Fabbri, et al. · Frontiers in Oncology · 3
PDF
Dynamic Changes of Peripheral NK Cells Predict Outcome in Patients with PD-L1 Positive Non-small-cell Lung Cancer Undergoing Immune Checkpoint Inhibitors as Second-line Therapy
2022 · Fabrizio Nelli, Valentina Panichi, et al. · Cancer Investigation · 3
Works count: 31
Citation count: 241
H-index: 10
I10-index: 10
Year
Topic
Type